Navigation Links
Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting
Date:9/26/2007

phine-induced constipation, while maintaining substantial central analgesic effect. In addition, orally-administered NKTR-118 had a favorable safety and pharmacokinetic profile in an animal model.

About NKTR-118

NKTR-118 is an oral drug that combines Nektar's advanced small molecule PEGylation technology platform with naloxol, a derivative of the opioid-antagonist drug, naloxone. In preclinical studies, Nektar's PEGylation technology has been shown to prevent oral NKTR-118 from crossing the blood-brain barrier, an important potential advance for this and possibly many other small molecule therapies.

The antagonist NKTR-118 targets mu-opioid receptors within the enteric nervous system, which mediate OBD, a symptom complex resulting from opioid use that encompasses constipation, bloating, abdominal cramping, and gastroesophageal reflux. Constipation is the hallmark of this syndrome, and is generally its most prominent component. NKTR-118 is currently in a second Phase 1 trial to evaluate the safety and tolerability of repeated dose administration.

According to IMS Health, more than 200 million prescriptions were written for opioids in 2006 in the United States, alone. Many studies indicate that a high percentage of patients receiving opioids are likely to experience significant constipation and other symptoms of OBD. Currently, there are no specific drugs approved that are indicated to treat OBD or OIC. Stool softeners or laxatives may be ineffective for many patients with OIC and they are often associated with side effects like diarrhea and cramping.

Data Presentations for NKTR-118

The NKTR-118 poster presentations from this week's American Academy of Pain Management's Annual Clinical Meeting in Las Vegas, Nevada from September 27-30, 2007 can be found on Nektar's website at http://www.nektar.com/wt/page/nktr118_media:

Poster #27: "Clinical Investigation
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... , May 4, 2015  The board of directors ... declared a dividend for the second quarter of 2015 of ... The dividend is payable June 10, 2015, to shareholders of ... About Eli Lilly and Company Lilly is a global ... better for people around the world. We were founded more ...
(Date:5/4/2015)... and TORONTO , May 4, 2015 ... today announced that it intends to dividend to its ... completion of a definitive licensing agreement to license its ... www.smoofi.com ) (OTCQB:SMFI). As announced on April ... intent in respect of the licensing of its RapidMist™ ...
(Date:5/4/2015)... May 4, 2015 PharmaEngine, Inc. (TWO:4162) ... Inc. (NASDAQ: MACK ) with its sublicensing ... jointly announced that Baxter has submitted a marketing ... (EMA) for MM-398 (irinotecan liposome injection), also known ... the pancreas who have been previously treated with ...
Breaking Medicine Technology:Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3
(Date:5/4/2015)... New Jersey (PRWEB) May 04, 2015 Parlin ... to give a chance to more youths to participate and ... encourage youths in her area to do good deeds and ... Dr.Blagoev intends to empower their minds and teach them to ... contest is accessible to any youth 18 years of age ...
(Date:5/4/2015)... May 05, 2015 The ... Irene Taylor , Volunteer Executive Director of ... 2015-2016 inductee into its VIP Woman of the ... distinction for leadership in business. NAPW is the ... boasting more than 700,000 members and over 200 ...
(Date:5/4/2015)... (PRWEB) May 05, 2015 The ... Patti Hommes as a 2015-2016 inductee into its ... with this prestigious distinction for leadership in business. NAPW ... women, boasting more than 700,000 members and over 200 ... with this important honor,” says NAPW President Star Jones. ...
(Date:5/4/2015)... 2015 The National Association of ... as a 2015-2016 inductee into the NAPW VIP ... this prestigious distinction for leadership in business. NAPW is ... boasting more than 700,000 members and over 200 operating ... this important honor," said NAPW President Star Jones. "Her ...
(Date:5/4/2015)... May 05, 2015 The National ... Weis as a 2015-2016 inductee into its VIP ... this prestigious distinction for leadership in healthcare. NAPW is ... boasting more than 700,000 members and over 200 operating ... this important honor,” says NAPW President Star Jones. “Her ...
Breaking Medicine News(10 mins):Health News:10 More Days To Enter Good Deed Contest 2Health News:National Association of Professional Women Inducts Irene Taylor into its 2015-2016 VIP Woman of the Year Circle 2Health News:NAPW Inducts Patti Hommes, Director of Advancement Services, Springside Chestnut Hill Academy, a 2015-2016 Professional Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Gloria Betancourt, Receptionist at Consulate Health Care, into its 2015-2016 VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Shirley Weis, President at Weis Associates, LLC, into its 2015-2016 VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Shirley Weis, President at Weis Associates, LLC, into its 2015-2016 VIP Woman of the Year Circle 3
... researchers older people have a less chance of surviving lung ... in time. On an average older people are more susceptible ... a ventilator.// What's not been clear is whether they do ... new study suggests that age is indeed a factor in ...
... of serotonin-raising drugs like antidepressants and slimming pills in ... of durgs is by increasing the levels of serotonin, ... body.// Examples include diet pills, anti-migraine drugs and some ... Health welfare hospital, warn of the potential dangers of ...
... patients on long-term non-steroidal anti-inflammatory drug (NSAID) treatment ... can substantially reduce the risk of ulcer formation.// ... cent of H.pylori infections and reduced the six-month ... the control group to 12 per cent in ...
... women whose jobs require too much exposure to solvents ... have chilren with defective eyesight. Head researcher Dr. Gideon ... of Occupational health. ,They found that poor ... mothers were frequently exposed to organic solvents at work ...
... School researchers have discovered nearly all the genes responsible ... blinding diseases.Macular degeneration affects 20 per cent of people ... photoreceptor genes expressed int he retinal cells, which was ... for preserving and restoring the vision of those affected.// ...
... People who suffer from asthma, particularly women, may have ... period of 30 years, researchers studied almost 100,000 patients ... of the patients showed any signs of cancer at ... second year after asthma diagnosis until the last day ...
Cached Medicine News:Health News:Genes for Vision discovered 2
Solid 14 mm blades. Dull finish....
Angled upward 45 degrees for temporal approach. Open 14 mm blades....
Pediatric model. Blades: 10 mm. Solid blades with locking mechanism. Dull finish....
Speculum with malleable plate to support flap during ablation of thestromal bed....
Medicine Products: